"rationale","uuid:ID","instanceType","versionIdentifier","id"
"The discontinuation rate associated with this oral dosing regimen was 58.6% in previous studies, and alternative clinical strategies have been sought to improve tolerance for the compound. To that end, development of a Transdermal Therapeutic System (TTS) has been initiated.","82f05f8b-3bb6-491a-8561-1d914fe02b5d","StudyVersion","2","StudyVersion_1"
